Salutary effects of 17beta-estradiol on Peyer's patch T cell functions following trauma-hemorrhage.
Although 17beta-estradiol (E2) administration following trauma-hemorrhage (T-H) improves immune functions in male rodents, it remains unclear whether E2 has salutary effects on Peyer's patch (PP) T cell functions. We hypothesized that T-H induces PP T cell dysfunction and E2 administration following T-H will improve PP T cell function. T-H was induced in male C3H/HeN mice (6-8weeks) by midline laparotomy and approximately 90min of hemorrhagic shock (blood pressure 35mmHg), followed by fluid resuscitation (4x the shed blood volume in the form of Ringer's lactate). Estrogen receptor (ER)-alpha agonist propyl pyrazole triol (PPT; 5microg/kg), ER-beta agonist diarylpropionitrile (DPN; 5microg/kg), E2 (50microg/kg), or vehicle was injected subcutaneously at resuscitation onset. Two hours later, mice were sacrificed and PP T cells isolated. PP T cell capacity to produce cytokines in response to in vitro stimulation, PP T cell proliferation and MAPK (p38, ERK-1/2, JNK) activation were measured. Results indicate PP T cell proliferation, cytokine production and MAPK activation decreased significantly following T-H. E2, PPT or DPN administration normalized these parameters. Since PPT or DPN administration following T-H was effective in normalizing PP T cell functions, the salutary effects of E2 are mediated via ER-alpha and ER-beta.
Kawasaki
Takashi
T
Center for Surgical Research and Department of Surgery, University of Alabama at Birmingham, G094 Volker Hall, 1670 University Boulevard, Birmingham, AL 35294, USA.
Suzuki
Takao
T
Choudhry
Mashkoor A
MA
Bland
Kirby I
KI
Chaudry
Irshad H
IH
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D016207:Cytokines / Q000096:biosynthesis; D004958:Estradiol / Q000494:pharmacology*; D047628:Estrogen Receptor alpha / Q000819:agonists; D047629:Estrogen Receptor beta / Q000819:agonists; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D048031:JNK Mitogen-Activated Protein Kinases / Q000378:metabolism; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D009570:Nitriles / Q000494:pharmacology; D010581:Peyer's Patches / Q000166:cytology* / Q000187:drug effects; D010636:Phenols; D011422:Propionates / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D012771:Shock, Hemorrhagic / Q000503:physiopathology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000502:physiology*; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
C486182:2,3-bis(4-hydroxyphenyl)-propionitrile; D016207:Cytokines; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D009570:Nitriles; D010636:Phenols; D011422:Propionates; D011720:Pyrazoles; C486184:4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol; D004958:Estradiol; D048049:Extracellular Signal-Regulated MAP Kinases; D048031:JNK Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases
Endocrinology. 1997 Jul;138(7):2919-27
9202236
Ann Surg. 1999 May;229(5):662-7; discussion 667-8
10235524
Mol Immunol. 2008 Jan;45(2):376-85
17673296
Eur J Surg. 1996 Apr;162(4):259-73
8739412
Am J Surg. 1993 Feb;165(2A Suppl):59S-67S
8439001
Crit Care Med. 2000 Apr;28(4 Suppl):N67-77
10807318
Immunology. 2000 Mar;99(3):464-72
10712678
J Biol Chem. 2000 Jun 2;275(22):16513-7
10748182
Infect Immun. 1980 Feb;27(2):461-7
6966611
Clin Exp Immunol. 1998 Sep;113(3):429-37
9737673
J Lab Clin Med. 1980 Jun;95(6):857-67
6966670
Annu Rev Immunol. 2002;20:761-94
11861617
Microbiol Mol Biol Rev. 2004 Jun;68(2):320-44
15187187
J Leukoc Biol. 2006 May;79(5):963-70
16478916
Cell Signal. 2009 Aug;21(8):1298-307
19324083
Shock. 2007 Mar;27(3):320-5
17304114
Am J Physiol. 1999 Jul;277(1):C35-42
10409106
J Immunol. 1993 Oct 1;151(7):3521-9
8376790
Immunol Rev. 2009 Mar;228(1):212-24
19290930
Immunol Cell Biol. 1995 Dec;73(6):484-8
8713469
Shock. 2004 May;21(5):391-400
15087814
J Leukoc Biol. 2005 Jan;77(1):16-23
15496450
Endocrinology. 2002 Nov;143(11):4172-7
12399409
Biochim Biophys Acta. 2005 Jun 30;1741(1-2):113-9
15955454
Trends Mol Med. 2005 Feb;11(2):56-63
15694867
Shock. 2005 Jun;23(6):527-32
15897805
Cytokine. 2008 Apr;42(1):32-8
18343154
Shock. 2000 Aug;14(2):81-90
10947147
Crit Care Med. 2001 Dec;29(12):2245-50
11801815
Am J Physiol Gastrointest Liver Physiol. 2002 Jun;282(6):G937-47
12016118
J Mol Cell Cardiol. 1997 Oct;29(10):2849-54
9344778
Trends Endocrinol Metab. 2002 Jul;13(5):220-5
12185669
Intensive Care Med. 2005 May;31(5):709-17
15782315
Shock. 2006 Nov;26(5):438-49
17047513
Shock. 2005 Dec;24(6):505-7
16317378
J Appl Physiol (1985). 2007 Jan;102(1):163-8
17023568
Am J Physiol Lung Cell Mol Physiol. 2006 May;290(5):L1004-9
16361351
J Leukoc Biol. 2004 Mar;75(3):400-7
14557385
Blood. 2000 Mar 15;95(6):2059-67
10706875
Shock. 2005 Feb;23(2):115-22
15665725
Shock. 1994 Apr;1(4):267-72
7735960
J Biol Chem. 2005 Aug 19;280(33):29409-19
15975924
Gen Pharmacol. 2000 Jul;35(1):1-9
11679199
Annu Rev Immunol. 2000;18:275-308
10837060
Immunol Cell Biol. 1995 Oct;73(5):389-96
8595915
Shock. 2005 Dec;24 Suppl 1:101-6
16374381
Endocr Metab Immune Disord Drug Targets. 2006 Jun;6(2):127-35
16787286
Clinics (Sao Paulo). 2006 Oct;61(5):479-88
17072448
J Leukoc Biol. 2005 Aug;78(2):565-73
15857937
Cytokine. 2006 Nov;36(3-4):107-14
17207634
Crit Care Med. 2006 Jan;34(1):182-7
16374173